Since type I interferon response gets hampered due to SARS-CoV-2, administering IFN systemically or locally either alone or with ribavirin [50, 83, 84], remdesivir [85, 86], lopinavir or ritonavir, and hydroxychloroquine can be a promising strategy against coinfection of COVID-19 with gynaecological cancer. Here, IFNA1 is linked to COVID-19.